In this multicenter randomized clinical trial conducted from September 15, 2021 to June 29, 2022 at 27 centers in China, investigators evaluated the efficacy and safety profile of batoclimab, an anti-IgG1 monoclonal antibody, in myasthenia gravis. A total of 178 adult patients with myasthenia gravis were screened, 132 were randomly assigned, 131 tested positive for antibodies and 1 tested negative for antibodies. Treatment cycles included 6 weekly subcutaneous injections of batoclimab 680 mg or placebo. Differences between patient groups were significant from the second week of treatment, with an advantage for the batoclimab group.
Last press reviews
HIV and Dual Therapy: a promising step towards maintaining viral suppression
The introduction of dual therapies in HIV treatment marks a significant ad...
HIV and Innate Immunity: How Early Responses Shape the Evolution of Viral Reservoirs
HIV infection remains a significant challenge in the field of infectious d...